.png)
Healios is Japan’s leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. Healios aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in cell therapy, having led the development of the first iPSC-derived technology used in humans in the world. Our somatic stem cell derived candidate, HLCM051, expected to show breakthrough effects in ARDS and stroke based on the results of past clinical trials and iPSC-derived candidate, HLCN061, is a next generation, functionally-enhanced NK cell treatment for solid tumors.